Trial site
Manchester
Manchester, M20 4BX, United KingdomNot linked to an institution yet
- 13running trials
- 6closed trials
The trials here
What the 19 trials at this site are about, from their registry records.
- Phase
- Phase 36 trials
- Phase 15 trials
- Phase 1/23 trials
- Phase 23 trials
- Phase 2/31 trial
- Status
- Recruiting8 trials
- Active, not recruiting5 trials
- Completed5 trials
- Terminated1 trial
- Lead sponsor
- GlaxoSmithKline18 trials
- Tesaro, Inc.1 trial
Running trials
Recruiting
First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy Adults
NCT07646353· Phase 1· GlaxoSmithKline· Source
Contact: Naimat Khan (principal investigator)
Recruiting
A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
NCT07602777· Phase 1/2· GlaxoSmithKline· Source
Contact: Alexander Lee (principal investigator)
Recruiting
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
NCT06961214· Phase 3· GlaxoSmithKline· Source
Contact: Thapas Nagarajan (principal investigator)
Recruiting
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
NCT06885034· Phase 1/2· GlaxoSmithKline· Source
Contact: Michael Braun (principal investigator)
Recruiting
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
NCT06847867· Phase 2· GlaxoSmithKline· Source
Contact: Daniel Wiseman (principal investigator)
Recruiting
A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive
NCT06433921· Phase 1· GlaxoSmithKline· Source
Contact: Dave Singh (principal investigator)
Active, not recruiting
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
NCT06154837· Phase 1· GlaxoSmithKline· Source
Recruiting
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200· Phase 3· GlaxoSmithKline· Source
Contact: Michael Braun (principal investigator)
Active, not recruiting
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT05277051· Phase 1· GlaxoSmithKline· Source
Active, not recruiting
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
NCT04915755· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy
NCT04655976· Phase 2/3· GlaxoSmithKline· Source
Recruiting
A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant
NCT04006808· Phase 1/2· GlaxoSmithKline· Source
Contact: Mohan Shenoy (principal investigator)
Active, not recruiting
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT02715284· Phase 1· Tesaro, Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error